Sugi Predict

Sugi Predict / Compounds / SCHEMBL264103

SCHEMBL264103

SCHEMBL264103

NS(=O)(=O)c1cccc(Br)c1

nearest known ligand 0.70

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 16/20 0.70
▸ CA1 P00915 12/20 0.70
▸ CA9 Q16790 13/20 0.59
▸ CA12 O43570 10/20 0.59
▸ CA14 Q9ULX7 5/20 0.59
▸ CA4 P22748 4/20 0.59
▸ CA7 P43166 5/20 0.52
▸ CA5A P35218 4/20 0.52
▸ CA6 P23280 2/20 0.52
▸ CA5B Q9Y2D0 2/20 0.52
▸ CA3 P07451 2/20 0.52
▸ PLA2G7 Q13093 1/20 0.52
▸ CA13 Q8N1Q1 1/20 0.52
▸ NOS1 P29475 1/20 0.47
▸ LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3531213 0.98 CA2 (0.67) CA2CA1CA9CA12CA14
Sulfuric Acid SCHEMBL28377517 0.92 CA2 (0.59) CA2CA1CA9CA12CA14
Boric Acid SCHEMBL28695399 0.92 CA2 (0.59) CA2CA1CA9CA12CA14
SCHEMBL28140019 0.84 CA2 (0.53) CA2CA1CA9CA12CA14
SCHEMBL2398133 0.83 CA2 (1.00) CA2CA1CA9CA12CA14
SCHEMBL24699123 0.83 CA2 (0.46) CA2CA1CA9CA12CA14
SCHEMBL30016630 0.83 CA2 (0.46) CA2CA1CA9CA12CA14
SCHEMBL31391247 0.81 LMNA (0.54) LMNA
SCHEMBL3679487 0.81 LMNA (0.54) LMNA
SCHEMBL31668877 0.81 LMNA (0.54) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 599 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528773-A N-alkylation method of sulfonamide compound 赣南医科大学 2025-02-28 — — CN claimed
CN-110857301-B Method for preparing TNNI3K inhibitor 南京理工大学 2022-07-22 — — CN claimed
CN-109422748-B Method for synthesizing TNNI3K inhibitor 南京理工大学 2021-06-22 — — CN claimed
CN-110857301-A Method for preparing TNNI3K inhibitor 南京理工大学 2020-03-03 — — CN claimed
CN-110642801-A Preparation method of parecoxib meta-isomer impurity 深圳市祥根生物科技有限公司 2020-01-03 — — CN claimed
EP-2616440-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES Adamed sp. z o.o. (PL) 2013-07-24 — — EP claimed
WO-2012035123-A1 ARYLOSULFONAMIDES FOR THE TREATMENT OF CNS DISEASES ADAMED SP. Z O.O. (PL) 2012-03-22 — — WO claimed
CN-101516837-A Sulfonamide derivatives HOFFMANN LA ROCHE (CH) 2009-08-26 — — CN claimed
EP-4719385-A2 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS University of Vermont and State Agricultural College (US) 2026-04-08 — — EP disclosed
US-12583824-B2 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity GENZYME CORPORATION (US) 2026-03-24 — — US disclosed
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-02-05 — — US disclosed
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-11-06 — — US disclosed
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF MAXYMUNE THERAPEUTICS INC (US) 2025-10-16 — — US disclosed
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof Maxymune Therapeutics, Inc. (US) 2025-09-30 — — US disclosed
US-5780490-A A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS SANKYO COMPANY, LIMITED (JP) 1998-07-14 — — US disclosed
WO-1998014185-A1 ANTITUMOR COMPOSITIONS AND METHODS OF TREATMENT ELI LILLY AND COMPANY (US) 1998-04-09 — — WO disclosed
US-5703096-A ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR SANKYO COMPANY, LIMITED (JP) 1997-12-30 — — US disclosed
CN-1143639-A Oxime derivatives, their preparation and their therapeutic use SANKYO CO (JP) 1997-02-26 — — CN disclosed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 — — EP disclosed
CN-1111453-A Aryl sulfonamide derivatives and pharmaceutical compositions containing the same NIPPON KOKAN KK (JP) 1995-11-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034123-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK1, CDK20 CA2 1909/4885CA1 2266/4885CA9 3099/4885
US-20250339388-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 CA2 3741/4885CA1 4697/4885CA9 4301/4885
US-12583824-B2 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity CFTR, CLIC1, NHERF1 CA2 993/4885CA1 4309/4885CA9 2606/4885
US-12427124-B1 Phenylalanine-based LAT1 inhibitors and uses thereof SLC43A1, SLC7A1, SLC1A5 CA2 3741/4885CA1 4697/4885CA9 4301/4885
US-20250319046-A1 PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF SLC43A1, SLC7A1, SLC1A5 CA2 3741/4885CA1 4697/4885CA9 4301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.